A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)
Sponsor: 1Globe Health Institute LLC
A PHASE3 clinical study on Previously Treated Metastatic Colorectal Cancer, this trial is ongoing. The trial is conducted by 1Globe Health Institute LLC and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE3
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 1Globe Health Institute LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Jinan, China and 9 more locations